Bexmarilimab clinical trials
Also written FP-1305.
How each study uses bexmarilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bexmarilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Faron Pharmaceuticals Ltd (4) · Institute of Cancer Research, United Kingdom (1) · MedSIR (1) · The University of Texas Health Science Center at San Antonio (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test bexmarilimab.
- Mar 2027A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesPhase 1/2 · Faron Pharmaceuticals Ltd
- Nov 2027Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic SyndromesPhase 2 · Faron Pharmaceuticals Ltd
Studies
Open first, then newest update. How each study uses bexmarilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic SyndromesRecruitingPhase 2Faron Pharmaceuticals LtdNCT07672769Written as bexmarilimab (1mg/kg)
- Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLCRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT07718243Written as Bexmarilimab 1mg/kg and nivolumab 1mg/kg
- A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.RecruitingPhase 1/2MedSIRNCT07460986Written as bexmarilimab
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesActive, not recruitingPhase 1/2Faron Pharmaceuticals LtdNCT05428969Written as Bexmarilimab
- A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)CompletedPhase 1/2Faron Pharmaceuticals LtdNCT03733990Written as FP-1305 (bexmarilimab)
- Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung CancerWithdrawnPhase 1The University of Texas Health Science Center at San AntonioNCT05171062Written as bexmarilimab (FP-1305)
- A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon CarcinomaWithdrawnPhase 1/2Faron Pharmaceuticals LtdNCT05104905Written as bexmarilimab
Codes
What other systems call bexmarilimab · ClinicalTrials.gg INT001972
- MeSH (NLM) C000723553bexmarilimabOne source ClinicalTrials.gov
- UNII (FDA) SA0O2AK3LABEXMARILIMABOne source FDA
- NCI Thesaurus C159536BexmarilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723553 | bexmarilimab | One source ClinicalTrials.gov |
| UNII (FDA) | SA0O2AK3LA | BEXMARILIMAB | One source FDA |
| NCI Thesaurus | C159536 | Bexmarilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.